title: On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.
abstract: OBJECTIVE
  To observe the natural course of gastro-oesophageal reflux disease (GERD) in patients without oesophagitis following effective symptom relief, and to determine the place of acid pump inhibitor therapy in the long-term management of these patients.
  
  
  METHODS
  We investigated the efficacy of on-demand therapy with omeprazole 20 mg or 10 mg, or placebo in a double-blind, randomized multicentre trial. It involved 424 patients with troublesome heartburn without endoscopic evidence of oesophagitis in whom heartburn had been resolved with short-term treatment. Patients were told to take study medication on demand once daily on recurrence of symptoms until symptoms resolved over a 6-month period. They also had access to antacids. The primary efficacy variable was time to discontinuation of treatment, due to unwillingness to continue.
  
  
  RESULTS
  According to life-table analysis, after 6 months the remission rates were 83% (95% CI: 77-89%) with omeprazole 20 mg, 69% (61-77%) with omeprazole 10 mg, and 56% (46-64%) with placebo (P < 0.01 for all intergroup differences). The mean (s.d.) number of study medications used per day in these groups was 0.43 (0.27), 0.41 (0.27) and 0.47 (0.27), respectively. The use of antacids was highest in the placebo group and lowest in the omeprazole 20 mg group. Treatment failure was associated with more than a doubling of antacid use, and a deterioration in patient quality of life.
  
  
  CONCLUSIONS
  Approximately 50% of patients with heartburn who do not have oesophagitis need acid inhibitory therapy in addition to antacid medication to maintain a normal quality of life. On-demand therapy with omeprazole 20 mg, is an effective treatment strategy in these patients.
authors.affiliation: Department of Surgery, Kärnsjukhuset, Skövde, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Lind
authors.forename: T
authors.initials: T
authors.lastname: Havelund
authors.forename: L
authors.initials: L
authors.lastname: Lundell
authors.forename: H
authors.initials: H
authors.lastname: Glise
authors.forename: K
authors.initials: K
authors.lastname: Lauritsen
authors.forename: S A
authors.initials: SA
authors.lastname: Pedersen
authors.forename: O
authors.initials: O
authors.lastname: Anker-Hansen
authors.forename: A
authors.initials: A
authors.lastname: Stubberöd
authors.forename: G
authors.initials: G
authors.lastname: Eriksson
authors.forename: R
authors.initials: R
authors.lastname: Carlsson
authors.forename: O
authors.initials: O
authors.lastname: Junghard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003718:Denmark; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004941:Esophagitis / Q000150:complications; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D010349:Patient Compliance; D054328:Proton Pump Inhibitors; D013548:Sweden; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D054328:Proton Pump Inhibitors; D009853:Omeprazole